全文获取类型
收费全文 | 7356篇 |
免费 | 351篇 |
国内免费 | 73篇 |
专业分类
耳鼻咽喉 | 72篇 |
儿科学 | 131篇 |
妇产科学 | 158篇 |
基础医学 | 815篇 |
口腔科学 | 133篇 |
临床医学 | 445篇 |
内科学 | 1957篇 |
皮肤病学 | 154篇 |
神经病学 | 455篇 |
特种医学 | 262篇 |
外科学 | 1477篇 |
综合类 | 18篇 |
一般理论 | 1篇 |
预防医学 | 178篇 |
眼科学 | 186篇 |
药学 | 351篇 |
中国医学 | 14篇 |
肿瘤学 | 973篇 |
出版年
2023年 | 58篇 |
2022年 | 43篇 |
2021年 | 177篇 |
2020年 | 116篇 |
2019年 | 137篇 |
2018年 | 211篇 |
2017年 | 146篇 |
2016年 | 166篇 |
2015年 | 198篇 |
2014年 | 250篇 |
2013年 | 315篇 |
2012年 | 534篇 |
2011年 | 616篇 |
2010年 | 344篇 |
2009年 | 302篇 |
2008年 | 553篇 |
2007年 | 567篇 |
2006年 | 500篇 |
2005年 | 490篇 |
2004年 | 447篇 |
2003年 | 448篇 |
2002年 | 386篇 |
2001年 | 64篇 |
2000年 | 47篇 |
1999年 | 60篇 |
1998年 | 83篇 |
1997年 | 53篇 |
1996年 | 57篇 |
1995年 | 42篇 |
1994年 | 55篇 |
1993年 | 38篇 |
1992年 | 32篇 |
1991年 | 23篇 |
1990年 | 17篇 |
1989年 | 23篇 |
1988年 | 28篇 |
1987年 | 20篇 |
1986年 | 12篇 |
1985年 | 9篇 |
1984年 | 15篇 |
1983年 | 12篇 |
1982年 | 14篇 |
1981年 | 12篇 |
1980年 | 8篇 |
1979年 | 3篇 |
1978年 | 13篇 |
1977年 | 11篇 |
1976年 | 3篇 |
1975年 | 7篇 |
1974年 | 3篇 |
排序方式: 共有7780条查询结果,搜索用时 15 毫秒
1.
Takafumi Koyama Toshio Shimizu Satoru Iwasa Yutaka Fujiwara Shunsuke Kondo Shigehisa Kitano Kan Yonemori Akihiko Shimomura Sakura Iizumi Tatsuya Sasaki Junji Furuse Noboru Yamamoto 《Cancer science》2020,111(2):571-579
Fibroblast growth factor receptors (FGFR) are a family of transmembrane receptor tyrosine kinases involved in regulating cellular processes. FGFR mutations are implicated in oncogenesis, representing therapeutic potential in the form of FGFR inhibitors. This phase I, first‐in‐human study in Japan evaluated safety and tolerability of E7090, a potent selective FGFR1‐3 inhibitor, in patients with advanced solid tumors. Dose escalation (daily oral dose of 1‐180 mg) was carried out to assess dose‐limiting toxicity (DLT), maximum tolerated dose, and pharmacokinetics. Pharmacodynamic markers (serum phosphate, fibroblast growth factor 23, and 1,25‐(OH)2‐vitamin D) were also evaluated. A total of 24 patients refractory to standard therapy or for whom no appropriate treatment was available were enrolled. No DLT were observed up to the 140‐mg dose; one patient in the 180‐mg cohort experienced a DLT (increased aspartate aminotransferase/alanine aminotransferase, grade 3). The maximum tolerated dose was not reached. Dose‐dependent increases in the maximum concentration and area under the curve from time 0 to the last measurable concentration were observed up to 180 mg. Dose‐dependent increases were observed in all pharmacodynamic markers and plateaued at 100‐140 mg, indicating sufficient FGFR pathway inhibition at doses ≥100 mg. In conclusion, E7090 showed a manageable safety profile with no DLT at doses ≤140 mg. Maximum tolerated dose was not determined. The recommended dose for the follow‐up expansion part, restricted to patients with tumors harboring FGFR alterations, was determined as 140 mg, once daily. 相似文献
2.
3.
4.
Satoru Motoyama Eri Maeda Katsunori Iijima Akira Anbai Yusuke Sato Akiyuki Wakita Yushi Nagaki Hiromu Fujita Yoshihiro Minamiya Takahiro Higashi 《Cancer science》2021,112(10):4281-4291
To address the major issue of regional disparity in the treatment for elderly cancer patients in an aging society, we compared the treatment strategies used for elderly patients with thoracic esophageal cancer and their survival outcomes in metropolitan areas and other regions. Using the national database of hospital-based cancer registries in 2008-2011, patients aged 75 years or older who had been diagnosed with thoracic esophageal cancer were enrolled. We divided the patients into two groups: those treated in metropolitan areas (Tokyo, Kanagawa, Osaka, Aichi, Saitama, and Chiba prefectures) with populations of 6 million or more and those treated in other areas (the other 41 prefectures). Compared were patient backgrounds, treatment strategies, and survival curves at each cancer stage. In total, 1236 (24%) patients from metropolitan areas and 3830 (76%) patients from nonmetropolitan areas were enrolled. Patients in metropolitan areas were treated at more advanced stages. There was also a difference in treatment strategy. The 3-year survival rate among cStage I patients was better in metropolitan areas (71.6% vs. 63.7%), and this finding mainly reflected the survival difference between patients treated with radiotherapy alone. For cStage II-IV patients, there were no differences. Multivariable Cox proportional hazard analysis including interaction terms between treatment areas, cStage, and the first-line treatments revealed that treatments in the metropolitan areas were significantly associated with better survival among patients treated with radiotherapy alone for cStage I cancer. Treatment strategies for elderly patients with thoracic esophageal cancer and its survival outcomes differed between metropolitan areas and other regions. 相似文献
5.
6.
7.
Aim: We report two patients with Panayiotopoulos syndrome (PS) who developed encephalopathy related to status epilepticus during slow sleep (ESES) at the peak of their clinical course. Methods: Clinical charts and EEG data were reviewed. Results: The patients exhibited nocturnal autonomic seizures and occipital EEG foci, the latter of which later evolved into multifocal EEG foci with synchronous frontopolar and occipital spikes (Fp‐O EEG foci), and finally into continuous spikes‐waves during sleep (CSWS; spike‐wave index >85% based on whole‐night sleep recording) at eight years and seven years of age, respectively. The occipital spikes always preceded frontopolar spikes by 30~50 mseconds based on the analysis of CSWS. Neuropsychological ability, including IQ, deteriorated during the CSWS period in both patients. The autonomic seizures and focal to bilateral tonic‐clonic seizures were initially resistant to antiepileptic drugs (AEDs), and occurred more than 10 times in both patients. However, the seizures and EEG findings gradually resolved, and AEDs were successfully terminated in both patients. Conclusion: PS can progress to ESES if the clinical course exhibits atypical evolution. The initial autonomic symptom of the seizures and interictal Fp‐O EEG foci should be carefully monitored in patients with CSWS or ESES. 相似文献
8.
9.
This report describes a unique case of a 56-year-old female who suffered from recurrent stroke after double mechanical valve replacement. During the four years after the surgery, she remained in normal sinus rhythm, received adequate anticoagulation therapy, and no apparent left atrial thrombus was detected. She underwent redo surgery to prevent further stroke after fourth instance of cerebral infarction. Intraoperative findings revealed a ‘dome-shaped’ pannus formation covering the sewing ring of the mitral prosthesis circumferentially, probably leading to clot formation and repeated infarctions. She has been stroke free for three years after pannus resection. 相似文献
10.